| 11.62 -0.01 (-0.09%) | 09-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 14.44 | 1-year : | 15.6 |
| Resists | First : | 12.36 | Second : | 13.35 |
| Pivot price | 11.82 |
|||
| Supports | First : | 10.76 | Second : | 8.95 |
| MAs | MA(5) : | 11.66 | MA(20) : | 12.1 |
| MA(100) : | 12.26 |
MA(250) : | 14.27 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 41.2 |
D(3) : | 43  |
| RSI | RSI(14): 43.9 |
|||
| 52-week | High : | 24.39 | Low : | 10 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CDTX ] has closed above bottom band by 39.6%. Bollinger Bands are 37.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 12.34 - 12.44 | 12.44 - 12.51 |
| Low: | 11.36 - 11.46 | 11.46 - 11.54 |
| Close: | 11.48 - 11.65 | 11.65 - 11.76 |
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
Tue, 17 Sep 2024
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Sees Large Decrease in Short Interest - MarketBeat
Mon, 16 Sep 2024
Cidara Therapeutics (NASDAQ:CDTX) Rating Reiterated by HC Wainwright - MarketBeat
Fri, 13 Sep 2024
Cidara therapeutics chief scientific officer sells shares worth over $10k - Investing.com
Fri, 13 Sep 2024
Cidara Therapeutics executive sells over $10k in company stock - Investing.com
Thu, 12 Sep 2024
Cidara Therapeutics Restructures Workforce to Focus on Planned Clinical Development of CD388 - GlobeNewswire
Thu, 12 Sep 2024
Cidara Therapeutics, Inc. Announces Reduction in Workforce to Focus on Planned Clinical Development of CD388 - Marketscreener.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 4.22e+006 (%) |
| Held by Institutions | 4.7 (%) |
| Shares Short | 101 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.011e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -211.4 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 675.8 % |
| Return on Equity (ttm) | -15.7 % |
| Qtrly Rev. Growth | 5.387e+007 % |
| Gross Profit (p.s.) | -91.36 |
| Sales Per Share | -148.93 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -24.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -125 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | -0.1 |
| Price to Book value | 0 |
| Price to Sales | -0.08 |
| Price to Cash Flow | 0.41 |
| Dividend | 0 |
| Forward Dividend | 76210 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|